Saltar al contenido
Merck

Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Journal of oncology (2010-07-17)
Thomas N Seyfried, Purna Mukherjee
RESUMEN

Progression of malignant brain tumors is dependent upon vascularity and is associated with altered ganglioside composition and distribution. Evidence is reviewed showing that the simple monosialoganglioside, GM3, possesses powerful antiangiogenic action against the highly vascularized CT-2A mouse astrocytoma, which primarily expresses complex gangliosides. Brain tumors expressing high levels of GM3 are generally less vascularized and grow slower than tumors that express low levels of GM3. GM3 inhibits angiogenesis through autocrine and paracrine effects on vascular endothelial growth factor (VEGF) and associated receptors. GM3 should be a clinically useful compound for managing brain tumor angiogenesis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Línea celular de glioma de ratón CT-2A, CT-2A mouse glioma cell line is a valuable mouse model for therapeutic research on brain malignancies.
Sigma-Aldrich
CT-2A-Luc Mouse Glioma Cell Line, CT-2A-Luc mouse glioma cell line is a valuable mouse model for therapeutic research on brain malignancies.